Welcome to our dedicated page for ImageneBio SEC filings (Ticker: IMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImageneBio, Inc. filings document a Nasdaq-listed biotechnology issuer focused on IMG-007, its anti-OX40 receptor antagonist program for autoimmune and inflammatory diseases. Its 8-K reports disclose operating results, program updates, Regulation FD materials, private-placement and capital-structure matters, and officer or director changes.
Proxy materials cover annual meeting proposals, director elections, auditor ratification, equity incentive plan amendments, and executive compensation governance. The filing record also identifies the company’s common stock on The Nasdaq Capital Market and records formal disclosures tied to its completed reverse-merger corporate history.
ImageneBio, Inc. reported first quarter 2026 results and highlighted progress for its lead OX40 antibody IMG-007 in atopic dermatitis and alopecia areata. License revenue was $0 versus $800,000 a year earlier as the company focuses on clinical development.
Research and development expenses rose to $6.0 million from $4.0 million, and general and administrative expenses increased to $6.1 million from $2.8 million. Net loss widened to $10.6 million from $9.1 million, reflecting higher operating costs.
Imagene ended March 31, 2026 with $117.2 million in cash, cash equivalents, and marketable securities and subsequently completed a $30 million private placement of pre-funded warrants. The company states this financing extends its cash runway into the first quarter of 2028 while it advances the Phase 2b ADAPTIVE trial of IMG-007 in atopic dermatitis and continues development in alopecia areata.
ImageneBio, Inc. is holding a virtual 2026 Annual Meeting on June 16, 2026, for stockholders of record as of April 28, 2026. Stockholders will vote on electing two Class II directors, ratifying PricewaterhouseCoopers LLP as auditor for 2026, and approving an amended 2025 Equity Incentive Plan.
The equity plan amendment would add 850,000 shares to the plan and revise its evergreen formula to factor in shares issuable upon conversion of preferred stock and cash exercise of prefunded warrants. As of April 28, 2026, 11,279,130 shares of common stock were outstanding, and equity awards included 1,187,218 options and 652,517 restricted stock units.
The proxy describes ImageneBio’s post‑merger governance structure, with a classified board, a non‑executive chair, a lead independent director, fully independent key committees, and policies covering risk oversight, insider trading, hedging, and director independence. It also details audit fees and confirms prior auditor transition from Ernst & Young LLP to PricewaterhouseCoopers LLP.
OrbiMed Advisors LLC and affiliated funds filed Amendment No. 6 to their Schedule 13D on ImageneBio, Inc. common stock. The filing reflects purchases of pre-funded warrants in the company’s 2026 private placement (2026 PIPE) and updates OrbiMed’s beneficial ownership.
OrbiMed now reports beneficial ownership of 1,495,045 Shares, including 721,292 Shares underlying presently exercisable Pre-Funded Warrants, representing 13.1% of ImageneBio’s 11,375,573 outstanding Shares. OrbiMed Private Investments VI, LP holds 1,089,665 Shares (including 336,603 Pre-Funded Warrants) and OrbiMed Genesis Master Fund, L.P. holds 405,380 Shares (including 384,689 Pre-Funded Warrants). A separate client, Worldwide Healthcare Trust PLC, holds 135,516 Shares. The 2026 PIPE Pre-Funded Warrants are priced at $5.199 each and include a 19.99% ownership blocker.
ImageneBio (Common Stock) is reported as having an aggregate of 1,176,472 shares beneficially owned by Trails Edge entities and Ortav Yehudai as of April 14, 2026. That holding comprises 54,253 shares held directly and 1,122,219 shares issuable upon pre-funded warrants, and is stated as 9.9% of the class based on 10,654,281 shares outstanding as of March 2, 2026.
Omega Fund VI and related reporting persons have disclosed a significant ownership position in ImageneBio, Inc. common stock. They report beneficial ownership of 936,222 shares, including 480,861 shares underlying pre-funded warrants held by Omega Fund, representing 8.4% of the company’s common stock.
The stake was built through ImageneBio’s (formerly Ikena Oncology) IPO, a 2025 PIPE financing and a 2026 PIPE financing. In 2026, Omega Fund bought pre-funded warrants for 480,861 shares at $5.199 per warrant share for total consideration of $2,499,996, as part of a broader $30 million pre-funded warrant issuance.
The warrants have a $0.001 exercise price, are exercisable at any time and do not expire, but contain a beneficial ownership limitation capped at 19.99%. The reporting persons describe the holding as an investment and indicate they may discuss strategic, governance, or transactional matters with ImageneBio’s board and other stockholders while reserving flexibility to increase or reduce their position.
ImageneBio, Inc. principal accounting officer Robert B. Lally filed an initial statement of beneficial ownership, reporting his equity interests in the company. He holds 58,778 shares of common stock, including 56,940 restricted stock units, plus an employee stock option for 25,410 shares at $6.20 per share expiring on March 15, 2036.
ImageneBio, Inc. director Su Wei-guo has filed an insider ownership report showing no reportable transactions or derivative positions. The filing’s transaction summary lists zero buys, zero sells, zero exercises, and no gifts, tax withholdings, or restructurings, indicating a baseline disclosure without trading activity.
ImageneBio director–affiliated investment funds made a sizable indirect purchase of pre-funded warrants. On the April 14, 2026 closing of a private placement, OrbiMed Private Investments VI, LP and OrbiMed Genesis Master Fund, L.P. acquired pre-funded warrants to buy a total of 721,292 shares of ImageneBio common stock at a price of $5.199 per warrant. These pre-funded warrants are exercisable at $0.001 per share and include a 19.99% beneficial ownership blocker. After the transactions, the OrbiMed funds also indirectly held 753,062 and 20,691 shares of common stock, and all entities, including director Bonita P. David, disclaim beneficial ownership beyond any pecuniary interest.
ImageneBio, Inc. reported that funds affiliated with OrbiMed purchased pre-funded warrants in a private placement. OrbiMed-related vehicles acquired pre-funded warrants to buy up to 721,292 shares of common stock at a price of $5.199 per warrant, with an exercise price of $0.001 per share.
The pre-funded warrants are exercisable at any time after issuance, subject to a 19.99% beneficial ownership blocker, and expire once fully exercised. The securities are held of record by OrbiMed Private Investments VI, LP and OrbiMed Genesis Master Fund, L.P., with OrbiMed entities and their principals disclaiming beneficial ownership beyond any pecuniary interest.